NOBEL PHARMACEUTICALS and TÜBİTAK MAM have launched a project to produce a national biosimilar drug molecule for use in cancer treatment.
Two long-established institutions in Türkiye, with a history spanning half a century, NOBEL PHARMACEUTICALS and TÜBİTAK MAM, are collaborating to develop and produce biotechnological molecules entirely from domestic resources, thus pioneering the establishment of a biotechnological drug production ecosystem.
Within the scope of the public R&D and domestic pharmaceutical industry partnership to be established with this project, a biosimilar of a biotechnological anticancer drug will be produced using entirely domestic resources for use in the treatment of patients with metastatic colorectal and head and neck cancer.
For this purpose, a recombinant cell bank capable of producing biosimilar drugs will be established, and in the pilot plant to be built, the production, purification, and analysis of the drug will be carried out, and phase studies will begin. TÜBİTAK MAM GMBE will undertake the tasks of ensuring the continuity of the knowledge and gains obtained from the project results as the "Responsible Project Implementing Organization (RPO)".
Note
If you have any photos or video footage to support our news story, please share them with us using the information provided on our contact us page.
